SURFACE ONCOLOGY INC (SURF) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SURF • US86877M2098

1.07 USD
-0.01 (-0.93%)
At close: Sep 7, 2023
1.07 USD
0 (0%)
After Hours: 9/7/2023, 8:23:11 PM
Fundamental Rating

2

Taking everything into account, SURF scores 2 out of 10 in our fundamental rating. SURF was compared to 524 industry peers in the Biotechnology industry. The financial health of SURF is average, but there are quite some concerns on its profitability. SURF is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SURF has reported negative net income.
  • SURF had a negative operating cash flow in the past year.
SURF Yearly Net Income VS EBIT VS OCF VS FCFSURF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

  • The profitability ratios for SURF are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURF Yearly ROA, ROE, ROICSURF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 200

1.3 Margins

  • SURF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURF Yearly Profit, Operating, Gross MarginsSURF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

  • SURF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SURF has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for SURF is higher compared to a year ago.
SURF Yearly Shares OutstandingSURF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
SURF Yearly Total Debt VS Total AssetsSURF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • SURF has an Altman-Z score of -6.54. This is a bad value and indicates that SURF is not financially healthy and even has some risk of bankruptcy.
  • SURF has a Altman-Z score of -6.54. This is in the lower half of the industry: SURF underperforms 72.65% of its industry peers.
  • SURF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.54
ROIC/WACCN/A
WACC9.86%
SURF Yearly LT Debt VS Equity VS FCFSURF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 3.60 indicates that SURF has no problem at all paying its short term obligations.
  • The Current ratio of SURF (3.60) is worse than 64.62% of its industry peers.
  • SURF has a Quick Ratio of 3.60. This indicates that SURF is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.60, SURF is doing worse than 64.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
SURF Yearly Current Assets VS Current LiabilitesSURF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

  • SURF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.60%.
  • Looking at the last year, SURF shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
  • The Revenue has been growing by 18.57% on average over the past years. This is quite good.
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 5.56% on average over the next years.
  • SURF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.55% yearly.
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SURF Yearly Revenue VS EstimatesSURF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
SURF Yearly EPS VS EstimatesSURF Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • SURF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SURF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SURF Price Earnings VS Forward Price EarningsSURF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURF Per share dataSURF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.95%
EPS Next 3Y6.29%

More info and screens

0

5. Dividend

5.1 Amount

  • SURF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURFACE ONCOLOGY INC

NASDAQ:SURF (9/7/2023, 8:23:11 PM)

After market: 1.07 0 (0%)

1.07

-0.01 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-02
Earnings (Next)10-31
Inst Owners1.16%
Inst Owner Change-96.44%
Ins Owners18.04%
Ins Owner Change0%
Market Cap65.08M
Revenue(TTM)N/A
Net Income(TTM)-92.50M
Analysts76.36
Price Target2.43 (127.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.65%
Min EPS beat(2)-33.43%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)-2.3%
Min EPS beat(4)-33.43%
Max EPS beat(4)18.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-54.6%
EPS NQ rev (1m)1.63%
EPS NQ rev (3m)-5.42%
EPS NY rev (1m)-11.28%
EPS NY rev (3m)-9.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.32
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -6.54
F-Score2
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)15.46%
Cap/Depr(5y)56.41%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%
EBIT growth 1Y-42.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-372.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-371.18%
OCF growth 3YN/A
OCF growth 5YN/A

SURFACE ONCOLOGY INC / SURF FAQ

Can you provide the ChartMill fundamental rating for SURFACE ONCOLOGY INC?

ChartMill assigns a fundamental rating of 2 / 10 to SURF.


What is the valuation status for SURF stock?

ChartMill assigns a valuation rating of 0 / 10 to SURFACE ONCOLOGY INC (SURF). This can be considered as Overvalued.


Can you provide the profitability details for SURFACE ONCOLOGY INC?

SURFACE ONCOLOGY INC (SURF) has a profitability rating of 0 / 10.


Can you provide the financial health for SURF stock?

The financial health rating of SURFACE ONCOLOGY INC (SURF) is 5 / 10.